<DOC>
	<DOCNO>NCT01276379</DOCNO>
	<brief_summary>Advanced colorectal cancer ( ACRC ) heterogeneous disease classification patient nowadays inefficient . Roughly twenty per cent patient present favorable figure ( less 4 liver nodule less 5 cm ) suitable local treatment ( surgery local-ablative therapy ) . Additionally , 10-15 % patient poor performance status ( PS &gt; 2 ) severe disable due geriatric syndrome or/and co-morbid disease preclude treatment strategy best supportive care alone . The rest patient ( fit patient suitable radical treatment ) constitute population patient treat palliative therapy . Despite patient prognosis . Patients PS 0,1 level LDH &lt; ULN ( Intermediate-risk patient ) good PFS OS irrespective therapy randomize clinical trial ( de Gramont et al , JCO 2000 ; Douillard et al , Lancet 2000 ; Koopman et al , 2007 ) . CRYSTAL trial show benefit PFS ( 1.5 month ) RASWT FOLFIRI plus cetuximab compare FOLFIRI alone . Nowadays selection patient cetuximab treatment base mutational status KRAS , allow select patient respond therapy . Other surrogate marker activity also evaluate . Our hypothesis suggest biomarkers allow selection patient benefit biweekly cetuximab treatment .</brief_summary>
	<brief_title>Study Evaluating Biomarkers Patients With Colorectal Cancer Native KRAS Treated With Chemotherapy + Cetuximab</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Male female , age ≥ 18 year Able sign inform consent form Advanced and/or metastatic colorectal cancer Colorectal cancer KRAS wild type genotype At least one unidimensionally measurable lesion accord RECIST criterion ( 1.1 revise ) ( assess ≤ 28 day prior study treatment ) All patient follow feature include : 1 . Progression free survival &gt; 6 month adjuvant treatment +/ radiotherapy 2 . `` De novo '' diagnosis disease Performance ECOG status 02 Life expectancy ≥ 3 month Adequate bone marrow function : neutrophil ≥1,5 x 10^9/L ; platelet ≥ 100 x 10^9/L ; hemoglobin ≥9 g/dL . Adequate liver , renal hematological function follow : 1 . Adequate liver function : SGOT SGPT 2.5 x ULN ( 5 x ULN case hepatic metastasis ) . Total bilirubin &lt; 1,5 x ULN . Alkaline phosphatase 2,5 x LSN ( 5 x ULN hepatic metastasis 10 x ULN bone metastasis ) 2 . Creatinine clearance creatinine clearance 24 hour ≥ 50 mL/min 3 . Magnesium ≥ LLN , calcium ≥ LLN PS &gt; 2 elderly patient fragility criteria Previous surgery metastasis Previous systemic treatment metastatic colorectal cancer Previous treatment antibody antiEGFR treatment smallmolecule EGFR tyrosine kinase inhibitor EGFR signal transduction inhibitor . Subjects suspend first dose due reaction infusion participate Central nervous system metastasis ( except : treated subject asymptomatic CNS metastasis receive steroid within 30 day prior inclusion ) Prior malignant tumor last 5 year , except : basal cell carcinoma skin preinvasive cervical cancer Unresolved toxicities prior systemic treatment qualify patient inclusion Presence peripheral neuropathy ( degree &gt; 1 ctc version 3.0 ) serious nonhealing wound , ulcer , bone fracture Hormonal treatment , immunotherapy experimental approve antibodies/proteins ≤ 30 day inclusion Uncontrolled serious cardiovascular disease : congestive cardiac failure NYHA lll lV , unstable angina pectoris , myocardial infarction precedent past 12 month , significant arrhythmias Interstitial pneumonitis pulmonary fibrosis precedent , interstitial pneumonitis pulmonary fibrosis sign thoracic CTscan Treatment systemic infection within 14 day prior treatment Acute/subacute intestinal occlusion and/or active inflammatory bowel disease bowel disease produce chronic diarrhea Precedent Gilbert 's syndrome dihydropyrimidine dehydrogenase deficiency Precedent disease increase risk associate participation study interfere study result Known positive test follow infection : HIV , Hepatitis C + abnormal liver enzyme value , active chronic Hepatitis B ( except Hepatitis C seropositive normal liver enzyme ) All concurrent diseases increase toxicity risk The individual present disorder kind jeopardizes ability give write consent form and/or fulfill study procedures Any investigational agent within 30 day enrolment Pregnant breastfeeding woman , plan get pregnant within 6 month treatment Surgery ( exclude diagnostic biopsy place central venous catheter ) Woman man childbearing potential consenting use adequate contraceptive precaution study 6 month de last administration woman , 1 month men Unability fulfill study requirement patient Psychological , family , sociological geographical condition may interfere fulfillment study protocol followup calendar</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>advanced</keyword>
	<keyword>metastatic</keyword>
	<keyword>KRAS</keyword>
	<keyword>biomarkers ( BRAF , IGF1P/MMp7 , PI3K-PTEN )</keyword>
	<keyword>cetuximab</keyword>
</DOC>